Burlington: MilliporeSigma, the Life Science business of Merck KGaA in the US and Canada, has recently introduced AIDDISON, a software for drug discovery.
The platform is designed to reduce the gap between molecule design and real-world manufacturing using Synthia retrosynthesis software application programming integration.
It is a one-of-a-kind solution designed to combine generative artificial intelligence, machine learning, and computer-aided drug design to speed up the drug development process.
AIDDISON has undergone extensive training for over twenty years of experimentally validated datasets.
It can efficiently recognize compounds with key drug properties, including non-toxicity, solubility, and stability, thereby exceeding 60 billion possibilities.
In a recent interview, MilliporeSigma said, “AI and machine learning models such as AIDDISON software can extract hidden insights from large datasets. In doing so, these models can increase the success rate of delivering new therapies to patients.”
By 2028, AI will help generate savings in the drug discovery process exceeding US$70 billion.
In addition, it can potentially reduce the overall time and costs by approximately 70% for the pharma-based companies involved in drug discovery.